(R,S)-4-hydroxy-2-(piperazin-1-yl)butanamide | 1265227-61-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R,S)-4-hydroxy-2-(piperazin-1-yl)butanamide
• 英文别名: 4-Hydroxy-2-piperazin-1-ylbutanamide
• CAS: 1265227-61-9
• 化学式: C₈H₁₇N₃O₂
• 分子量: 187.242
• InChiKey: MTMLZDTYEUFDOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  78.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (R,S)-ethyl 4-(1-amino-4-hydroxy-1-oxobutan-2-yl)piperazine-1-carboxylate 在 三氟乙酸 、 potassium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 1.0h， 以26%的产率得到(R,S)-4-hydroxy-2-(piperazin-1-yl)butanamide
  参考文献：
  名称：

  Synthesis and biological evaluation of new derivatives of 2-substituted 4-hydroxybutanamides as GABA uptake inhibitors

  摘要：

  This study presents the synthesis of novel substituted 4-hydroxybutanamides and their influence on the activity of murine GABA transport proteins GAT1-GAT4. The active compounds, derivatives of N-aryl-alkyl-2-(4-diphenylmethylpiperazin-1-yl)-4-hydroxybutyramide, are characterized by pIC(50) values in range of 3.92-5.06 and by slight subtype-selectivity. Among them N-4-chlorobenzylamide was the most potent GAT inhibitor (mGAT3), while N-benzylamide was the most active in GAT1-binding assay (pK(i) = 4.96). The results pointed out that benzhydryl and benzylamide moieties are crucial for the activity of this class of compounds as murine GAT inhibitors. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.11.001

文献信息

• PYRROLOPYRIDINE INHIBITORS OF KINASES
  申请人：Florjancic Alan S.

  公开号：US20110015173A1

  公开（公告）日：2011-01-20

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1a , R 1b , R 1c , X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

  本发明涉及公式（I）的化合物或药用可接受的盐，其中R1a、R1b、R1c、X和Y在描述中有定义。本发明还涉及含有上述化合物的组合物，该组合物对抑制Cdc7等激酶以及治疗癌症等疾病有用。
• Pyrimidine A2B selective antagonist compounds, their synthesis and use
  申请人：Castelhano Arlindo

  公开号：US20050119271A1

  公开（公告）日：2005-06-02

  The subject invention provides compounds having the structure: wherein R 1 is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R 2 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)-O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety; R 3 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)-O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R 2 and R 3 are joined to form a heterocyclic ring; wherein the dashed line represents a second bond which may be present or absent, and when present R 3 is oxygen; R 4 and R 5 are each independently substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)-O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R 4 NR 5 together form a substituted or unsubstituted monocyclic or bicyclic, heterocyclic or heteroaryl moiety containing from 1 to 6 heteroatoms; R 12 is hydrogen, alkyl, halogen or cyano; and n is 0, 1, 2, 3 or 4, or an enantiomer, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating a disease associated with the A 2b adenosine receptor by administering a therapeutically effective amount of the compounds of the invention.

  本发明提供具有以下结构的化合物： 其中，R1是取代或未取代的苯基或含有1至5个杂原子的5-6元杂环或杂芳基环；R2是氢，或取代或未取代的烷基，-C(O)-烷基，-C(O)-O-烷基，烷氧基，环烷基，烯基，单环或双环芳基，杂芳基或杂环基；R3是氢，或取代或未取代的烷基，-C(O)-烷基，-C(O)-O-烷基，烷氧基，环烷基，烯基，单环或双环芳基，杂芳基或杂环基；或R2和R3结合形成杂环环；其中虚线表示第二键可能存在或不存在，当存在时，R3是氧；R4和R5分别是取代或未取代的烷基，-C(O)-烷基，-C(O)-O-烷基，烷氧基，环烷基，烯基，单环或双环芳基，杂芳基或杂环基；或R4NR5一起形成含有1至6个杂原子的取代或未取代的单环或双环，杂环或杂芳基；R12是氢，烷基，卤素或氰基；n为0、1、2、3或4，或其对映异构体，或其特定互变异构体，或其药学上可接受的盐，并提供了一种通过给予本发明化合物的治疗有效量来治疗与A2b腺苷受体相关的疾病的方法。
• US6916804B2
  申请人：——

  公开号：US6916804B2

  公开（公告）日：2005-07-12
• US7501407B2
  申请人：——

  公开号：US7501407B2

  公开（公告）日：2009-03-10
• US8435980B2
  申请人：——

  公开号：US8435980B2

  公开（公告）日：2013-05-07